Table 1. Effect of brigatinib’s and alectinib’s drug targets in ALK+ NSCLC.

Pathophysiological processes (motives)	Brigatinib’s targets						Alectinib’s targets
	ALK	FLT3	FER	ROS1	IGF1R	EGFR	ALK	RET
NSCLC ALK+	++	+	+	+	+	+++	++	+
Cell growth and proliferation	+++	++	++	+	+++	+++	+++	+
Evading apoptosis	+++	++	+	+	++	++++	+++	+
Sustained angiogenesis	+	+	++	+	+++	+	+	+
Tissue invasion and metastasis	+	+	++	+	++	++	+	+
Immune evasion	+++	+++	+	+	+	++	+++	++++

Relationship of brigatinib’s and alectinib’s targets and pathophysiological motives calculated by artificial neural networks (ANN). High (++++) corresponds to p-value < 0.05, Medium-high (+++) corresponds to p-values < 0.15 and Medium (++) corresponds to p-value < 0.25, while Low (+) correspond to p-value > 0.25.